Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Toshiyuki Tamai
Eisai, Inc.
Tokyo
Japan
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
69
TOTAL CITATIONS
1
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Overall Survival and Objective Response in Advanced Unresectable Hepatocellular Carcinoma: A Subanalysis of the REFLECT Study
Number of pages: 35
Posted: 08 Feb 2020
Masatoshi Kudo
,
Richard S. Finn
,
Shukui Qin
,
Kwang-Hyub Han
,
Kenji Ikeda
,
Ann-Lii Cheng
,
Francesco Tovoli
,
Kazuomi Ueshima
,
Hiroshi Aikata
,
Arndt Vogel
,
Carlos López López
,
Marc Pracht
,
Zhiqiang Meng
,
Bruno Daniele
,
Joong-Won Park
,
Daniel Palmer
,
Corina E. Dutcus
, Toshiyuki Tamai,
Kenichi Saito
and
Riccardo Lencioni
Kindai University - Department of Gastroenterology and Hepatology, University of California, Los Angeles (UCLA) - David Geffen School of Medicine, Nanjing Bayi Hospital, Yonsei University - Severance Hospital, Toranomon Hospital - Department of Hepatology, National Taiwan University - Department of Internal Medicine, University of Bologna, Kindai University - Faculty of Medicine, Hiroshima University - Hiroshima University Hospital, Hannover Medical School - Department of Gastroenterology, Hepatology and Endocrinology, Hospital Marqués de Valdecilla, Comprehensive Cancer Center Eugène Marquis, Fudan University - Shanghai Cancer Center (FUSCC), Azienda Ospedaliera G. Rummo, National Cancer Center, Korea, Clatterbridge Cancer Centre, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc., Eisai, Inc. - Eisai, Inc. - United States and University of Miami - Miller School of Medicine
Downloads
69
(883,195)
Citation
1
View PDF
Download
Abstract:
landmark analysis; lenvatinib; mRECIST; response status; surrogate endpoint
Feedback